8-K: BIO-key Q2 Revenue Jumps 49% on Biometric Sales

BIO-key International reports significant Q2 2025 revenue growth driven by increased sales across all three segments and launches a new CyberDefense Initiative.

Summary

• Total revenues for Q2 2025 increased 49% to $1,696,907, up from $1,141,286 in Q2 2024.
• The net loss for Q2 2025 improved to ($1,167,396), or ($0.20) per share, compared to ($1,666,950), or ($1.00) per share, in Q2 2024.
• Gross profit increased 40% to $1,232,727 in Q2 2025, with gross margins moderating to 73% from 77% in Q2 2024 due to higher hardware sales.
• Total operating expenses decreased by 8.5% to $2,316,577 in Q2 2025, primarily due to a 13.5% reduction in selling, general, and administrative (SG&A) expenses.
• Cash and cash equivalents increased to $2.27 million as of June 30, 2025, up from $0.44 million at December 31, 2024.
• The company launched the BIO-key CyberDefense Initiative to pursue opportunities in the global defense market, leveraging increased European defense spending commitments.
• Key customer wins include over $600,000 in follow-on orders from a Foreign Defense Ministry, a major IAM deployment with a National Bank in Mozambique, and an initial phase biometric deployment for a new International Defense Agency customer.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth, significant improvement in net loss and EPS, effective cost reduction, and a substantial increase in cash. The launch of a strategic CyberDefense Initiative targeting a growing market further enhances the positive outlook, despite continued net losses and a slight moderation in gross margin.

Positives

• Q2 2025 revenues increased significantly by 49% year-over-year, reaching $1,696,907.
• Net loss improved substantially to ($1,167,396) in Q2 2025 from ($1,666,950) in Q2 2024.
• Loss per share improved to ($0.20) in Q2 2025 from ($1.00) in Q2 2024.
• Total operating expenses decreased by 8.5% to $2,316,577, reflecting effective cost reduction efforts.
• Selling, general, and administrative (SG&A) expenses were reduced by 13.5% compared to the prior year.
• Cash and cash equivalents increased significantly to $2.27 million as of June 30, 2025, from $0.44 million at December 31, 2024.
• The company successfully secured over $600,000 in follow-on orders from a Foreign Defense Ministry.
• A first major Identity and Access Management (IAM) deployment was secured with a National Bank in Mozambique.
• Initial phase biometric-based deployment was completed for a new International Defense Agency customer.
• The launch of the BIO-key CyberDefense Initiative strategically positions the company to capitalize on growing global defense spending and cyber resilience priorities.

Negatives

• Gross margin moderated to 73% in Q2 2025 from 77% in Q2 2024, primarily due to an increase in lower-margin hardware sales as a percentage of total revenue.
• The company continues to report a net loss of ($1,167,396) for the quarter.
• Research, development, and engineering (R&D) expenses increased by 7.6% to $636,027, although this is attributed to platform modernization efforts.

Risks

• History of losses and limited revenue.
• Ability to raise additional capital to satisfy working capital needs.
• Ability to continue as a going concern.
• Ability to protect intellectual property.
• Changes in business conditions, sales strategy, and product development plans.
• Changes in the marketplace and competition in the biometric technology and identity access management industries.
• Ability to convert sales opportunities to customer contracts.
• Ability to expand into Asia, Africa, and other foreign markets.
• Security breaches.
• Fluctuations in foreign currency exchange rates.
• The duration and extent of continued hostilities in Ukraine and its impact on European customers.
• The impact of tariffs and other trade barriers.
• Delays in the development of products.
• Commercial, reputational, and regulatory risks arising from the restatement of financial statements, including non-compliance with SEC and Nasdaq reporting requirements.
• Temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future.
• Any disruption to the business should the company be unable to maintain effective internal controls over financial reporting.

Future Outlook

The company is optimistic about its growth outlook, expecting meaningful contract activity in the first half of next year from the BIO-key CyberDefense Initiative. A significant platform modernization and deployment improvements for PortalGuard IDaaS are targeted for release in Q4 2025. Management continues to pursue opportunities to reduce costs and lower its breakeven level to support a path to positive cash flow and profitability in 2025, while acknowledging that the timing of large customer orders or renewals may cause quarter-to-quarter fluctuations in financial performance.

Management Comments

• "BIO-key’s Q2 revenue improved both sequentially and versus last year as we make steady progress advancing our direct and channel sales efforts which have been refocused solely on BIO-key branded solutions principally in Europe, Middle East and Africa (EMEA) as well as domestic markets."
• "We are pursuing the substantial potential for IAM and biometric enabled solutions within the global defense market... We expect this initiative to be supported by the recent and significant ramp in European defense spending commitments, including the clear shift toward cyber resilience as a security priority for European nations."
• "We believe BIO-key’s successful track record in providing efficient, robust and highly secure authentication and identification solutions to the most discriminating defense sector IT groups puts us in a very strong position to capitalize on this opportunity both in Europe and around the globe."
• "With a robust pipeline of existing opportunities, based on expected procurement cycles, we expect to see meaningful contract activity in the first half of next year."
• "With increasing interest in our biometric solutions, growing adoption of passwordless, phoneless and tokenless IAM solutions, a strong margin profile, and revenue traction in EMEA markets, we are optimistic about our growth outlook."
• "We feel that the security, flexibility, ease of deployment and the compelling ROI of our solutions, combined with growing market acceptance of the need, should position us to deliver improved topand bottom-line results in 2025."
• "We also continue to pursue opportunities to reduce costs and lower our breakeven level to support our path to positive cash flow and profitability, while balancing these efforts with our product development and marketing efforts."

Industry Context

The announcement aligns with broader industry trends showing a significant increase in global defense spending, particularly in Europe, with a clear shift towards cyber resilience as a security priority. This creates a substantial market opportunity for Identity and Access Management (IAM) and biometric-enabled solutions. The growing adoption of passwordless, phoneless, and tokenless IAM solutions also indicates a market shift towards more secure and convenient authentication methods, which BIO-key's offerings directly address.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess BIO-key's performance against global industry benchmarks. Therefore, a direct comparison to industry standards based solely on the provided information is not feasible.

Stakeholder Impact

• Shareholders: Potential for improved financial performance and future profitability, as evidenced by reduced losses and increased cash, but also continued dilution from warrant exercises and ongoing net losses.
• Employees: Continued investment in R&D and global sales efforts suggests stability and potential growth opportunities.
• Customers: Benefit from new deployments, strategic partnerships, and upcoming platform modernization (PortalGuard IDaaS) for enhanced security and user experience.
• Creditors: Reduction in note payable balance indicates improved financial health and debt management.
• Partners: Expansion of partnerships in the Middle East (Cloud Distribution Co. of Saudi Arabia) and Europe (Arrow ECS Iberia) indicates growing collaboration and market reach.

Next Steps

• Host an investor call on August 13, 2025, at 10:00 AM ET to discuss Q2 2025 results.
• Target the release of a significant platform modernization and deployment improvements for PortalGuard IDaaS in Q4 2025.
• Pursue meaningful contract activity in the first half of 2026 through the BIO-key CyberDefense Initiative.
• Continue efforts to reduce costs and lower the breakeven level to achieve positive cash flow and profitability in 2025.

Key Dates

Recommendation

While BIO-key demonstrated strong revenue growth and significant improvements in net loss and cash position, the company continues to operate at a net loss and faces ongoing risks, including the need for additional capital and the ability to continue as a going concern. The strategic CyberDefense Initiative and PortalGuard modernization offer future upside, but the company's historical performance and the competitive landscape warrant a cautious 'hold' recommendation until a clear path to sustained profitability and positive cash flow is demonstrated.

Keywords

Biometrics, Identity and Access Management, IAM, Cybersecurity, Passwordless, Authentication, Defense, CyberDefense, Enterprise Security, Financial Results, Q2 2025, Nasdaq BKYI